DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced the pricing of an underwritten public offering of 47,619,048 shares of its common stock at a public offering price of $1.05 per share. The aggregate gross proceeds from this offering are expected to be $50 million, before deducting underwriting discounts and commissions and other offering expenses payable by Humacyte. The closing of the offering is expected to occur on or about June 12, 2026, subject to the satisfaction of customary closing conditions. In addition, Humacyte has granted the underwriters an option for a period of 30 days to purchase up to an additional 7,142,857 shares of Humacyte’s common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being sold by Humacyte.
OKOTOKS, AB, June 10, 2026 /CNW/ - Replenish Nutrients Holding Corp. (CSE: ERTH) (OTC: VVIVF) ("Replenish" or the "Company"), is pleased to announce that it...
/THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES./TORONTO, June 10, 2026 /CNW/ - Canada...
CHICAGO, June 10, 2026 /PRNewswire/ -- CME Group, the world's leading derivatives marketplace, along with Morningstar, a leading provider of independent investment insights, today...
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Zillow (Z) To Contact Him Directly To Discuss Their Options
WOODLAND PARK, N.J., June 10, 2026 (GLOBE NEWSWIRE) -- Anterix (NASDAQ: ATEX) today announced fiscal 2026 fourth quarter and full fiscal year financial results for the year ended March 31, 2026.
New York, NY, June 10, 2026 (GLOBE NEWSWIRE) -- byNordic Acquisition Corporation (“BYNO” or the “Company”), a special purpose acquisition company, announced today that the Company has timely deposited into the Company’s trust account (the “Trust Account”), an aggregate of $17,470, in order to extend the period of time the Company has to complete a business combination for an additional one (1) month period, from June 12, 2026 to July 12, 2026 (the “Extension”). The Extension is the eleventh of up to twelve (12) one-month extensions permitted under the August 8, 2025 amendment to the Company’s Amended and Restated Certificate of Incorporation that allows the Company’s board of directors, in its sole discretion and without another stockholder vote, to elect to extend the termination date by one additional month each time up until August 12, 2026, or the closing of the Company’s initial business combination.
TEL AVIV, Israel, June 10, 2026 (GLOBE NEWSWIRE) -- ZOOZ Strategy Ltd. (Nasdaq and TASE: ZOOZ) (“ZOOZ” or the “Company”) today announced that its Board of Directors has authorized management to explore a range of strategic alternatives that could potentially complement the Company’s existing bitcoin treasury strategy and enhance long-term shareholder value.
Certification Equips U.S. Government Agencies to Transform Customer ExperienceSAN FRANCISCO and NEW YORK, June 10, 2026 /PRNewswire/ -- Sierra, the leading AI-powered customer experience platform,...
Check Point gains access to GPT-5.5 with Trusted Access for Cyber for high-stakes defensive security operations and dedicated support from OpenAI's cybersecurity teamREDWOOD CITY,...